Showing results (1-10 of 58) with videos related to
Sort By:
Pageof 6
Haematologica|July 16, 2026
What's liver got to do with it? Hepatic response and survival in AL amyloidosisJeffrey A ZonderHematology. American Society of Hematology. Education Program|November 25, 2006
Thrombotic complications of myeloma therapyJeffrey A ZonderBlood and Lymphatic Cancer : Targets and Therapy|July 31, 2019
Use of carfilzomib in second-line therapy and beyond for relapsed multiple myelomaDivaya Bhutani, Jeffrey A ZonderCurrent Hematologic Malignancy Reports|April 29, 2010
Update on practical aspects of the treatment of chronic myeloid leukemia with imatinib mesylateJeffrey A Zonder, Charles A SchifferCurrent Cancer Drug Targets|August 6, 2014
Overview of proteasome inhibitor-based anti-cancer therapies: perspective on bortezomib and second generation proteasome inhibitors versus future generation inhibitors of ubiquitin-proteasome systemQ Ping Dou, Jeffrey A ZonderCurrent Hematology Reports|August 7, 2003
Practical aspects of the treatment of chronic myelogenous leukemia with imatinib mesylateJeffrey A Zonder, Charles A SchifferHematology/Oncology Clinics of North America|October 25, 2020
The Spectrum of Monoclonal Immunoglobulin-Associated DiseasesSascha A Tuchman, Jeffrey A ZonderExpert Opinion on Investigational Drugs|June 10, 2009
Clinical development of novel proteasome inhibitors for cancer treatmentHuanjie Yang, Jeffrey A Zonder, Q Ping DouAmerican Journal of Hematology|November 26, 2002
Chronic lymphocytic leukemia presenting in association with aplastic anemiaJeffrey A Zonder, Michael Keating, Charles A SchifferAdvances in Hematology|August 2, 2012
Secondary primary malignancies in multiple myeloma: an old NEMESIS revisitedJay Yang, Howard R Terebelo, Jeffrey A ZonderPageof 6